Next Article in Journal
Creating Disease Resistant Chickens: A Viable Solution to Avian Influenza?
Next Article in Special Issue
A Comprehensive Superposition of Viral Polymerase Structures
Previous Article in Journal
Role of Host Cell Secretory Machinery in Zika Virus Life Cycle
Previous Article in Special Issue
RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution
Open AccessReview

Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine

1
Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, New York, NY 14642, USA
2
Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, Colorado, CO 80523, USA
*
Authors to whom correspondence should be addressed.
Viruses 2018, 10(10), 560; https://doi.org/10.3390/v10100560
Received: 25 August 2018 / Revised: 3 October 2018 / Accepted: 12 October 2018 / Published: 15 October 2018
(This article belongs to the Special Issue Structure-Function Relationships in Viral Polymerases)
Live attenuated influenza vaccines (LAIV) have prevented morbidity and mortality associated with influenza viral infections for many years and represent the best therapeutic option to protect against influenza viral infections in humans. However, the development of LAIV has traditionally relied on empirical methods, such as the adaptation of viruses to replicate at low temperatures. These approaches require an extensive investment of time and resources before identifying potential vaccine candidates that can be safely implemented as LAIV to protect humans. In addition, the mechanism of attenuation of these vaccines is poorly understood in some cases. Importantly, LAIV are more efficacious than inactivated vaccines because their ability to mount efficient innate and adaptive humoral and cellular immune responses. Therefore, the design of potential LAIV based on known properties of viral proteins appears to be a highly appropriate option for the treatment of influenza viral infections. For that, the viral RNA synthesis machinery has been a research focus to identify key amino acid substitutions that can lead to viral attenuation and their use in safe, immunogenic, and protective LAIV. In this review, we discuss the potential to manipulate the influenza viral RNA-dependent RNA polymerase (RdRp) complex to generate attenuated forms of the virus that can be used as LAIV for the treatment of influenza viral infections, one of the current and most effective prophylactic options for the control of influenza in humans. View Full-Text
Keywords: influenza virus; influenza vaccine; live-attenuated influenza virus; recombinant influenza virus; viral polymerase complex; nucleoprotein; temperature-sensitive; cold-adapted; attenuated influenza virus; influenza vaccine; live-attenuated influenza virus; recombinant influenza virus; viral polymerase complex; nucleoprotein; temperature-sensitive; cold-adapted; attenuated
Show Figures

Figure 1

MDPI and ACS Style

Martínez-Sobrido, L.; Peersen, O.; Nogales, A. Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine. Viruses 2018, 10, 560.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop